Immunovia Publishes the Annual Report for the Financial Year 2019

Immunovia Publishes the Annual Report for the Financial Year 2019

PR Newswire

LUND, Sweden, March 20, 2020

LUND, Sweden, March 20, 2020 /PRNewswire/ --

Immunovia has today published the annual report for 2019. It is available on Immunovia's website.

Mats Grahn, CEO, comments: "In December 2019, we reached a very important milestone with the results of the "Commercial Test Model Study", which showed 95% accuracy for IMMray™ PanCan-d, our product for diagnosing pancreatic cancer at an early stage when it is still possible to successfully remove the tumor surgically. This result paves the way for considerable improved treatment and survival rates for patients with this deadly disease. We are now fully focused on launching our blood-based test in Q3 2020.

As we close 2019, we continue to make great strides and remain on track to launch our lead diagnostic candidate IMMray™ PanCan-d in the US market during Q3 2020. We ended the year with fantastic results from our "Commercial Test Model Study," which confirmed the very high accuracy of our test in differentiating stages I-IV of pancreatic cancer from clinically relevant control groups that best reflect the commercial and clinical situation (i.e. patients who do not have cancer but show similarly concerning symptoms, including type 2 diabetes, as well as healthy subjects). In 2019, we not only achieved the milestones needed to advance towards the commercialization of IMMray™ PanCan-d, but we also made progress with our pipeline projects in lung cancer and autoimmune diseases."

Major highlights include:

The annual report is available on Immunovia's website: immunovia.com/en/investors/financial-reports/ and is also attached below.

The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on March 20, 2020.

For more information, please contact:
Julie Silber, Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-publishes-the-annual-report-for-the-financial-year-2019,c3064478

The following files are available for download:

https://mb.cision.com/Main/13121/3064478/1214667.pdf

Release

 

Voltar noticias em Inglês